Simvastatin-induced erythromelalgia: less is more

Area of Science:

• Clinical Medicine
• Pharmacology
• Dermatology

Background:

• Erythromelalgia is a rare, debilitating condition characterized by intense burning pain and redness, typically in the extremities.
• Diagnosis is often delayed due to its rarity and the need for exclusion of other conditions.
• It can be secondary to various systemic diseases or, notably, pharmacological agents.

Observation:

• A patient with Type 2 diabetes mellitus presented with severe burning leg pain and redness, relieved only by cooling.
• Initial misdiagnosis and treatment with analgesics and amitriptyline occurred due to unfamiliarity with erythromelalgia.
• Symptoms resolved after empirical discontinuation of simvastatin.

Findings:

• The case suggests a potential link between simvastatin use and the development of erythromelalgia.
• This highlights the possibility that HMG CoA Reductase inhibitors (statins) may induce or exacerbate erythromelalgia.
• Erythromelalgia, in this context, was likely a drug-induced adverse effect.

Implications:

• Clinicians should consider drug-induced erythromelalgia, particularly with statin use, in patients presenting with characteristic symptoms.
• Awareness of statin-induced erythromelalgia can prevent diagnostic delays and inappropriate treatments.
• Further investigation into the role of statins and other HMG CoA Reductase inhibitors in causing erythromelalgia is warranted.